A new study from University of Michigan Rogel Cancer Centre researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.

Treatments such as enzalutamide, which is an androgen receptor pathway inhibitor (ARPI), are standard of care for advanced prostate cancer.

While many patients have long-term good response to the drugs, some will derive no benefit whatsoever.

These “extreme non-responder” patients die much more quickly from prostate cancer.

The new study, published in npj Precision Oncology, looked at RNA sequencing data and clinical outcomes from several prostate cancer clinical trial datasets.

The researchers identified a gene programme linked to ARPI extreme non-response.

Moreover, they discovered the chemotherapy docetaxel could be a good option earlier on in patients whose tumour harbours the ARPI extreme non-response programme.

Docetaxel is approved for prostate cancer but typically given later in the course of treatment.

“We found significant differences in the gene expression programme between prostate cancers that do exceptionally well vs. exceptionally poorly with ARPIs. Patients who have this extreme non-response programme appear to get significant benefit from docetaxel, suggesting these patients may be good candidates for earlier docetaxel treatment,” said lead first author Anbarasu Kumaraswamy, Ph.D., an investigator in the Alumkal Lab at the Rogel Cancer Centre.

The researchers also found that the kinase CDK2 regulates the extreme non-response programme, and targeting CDK2 could block the programme and reduce tumour growth in the laboratory samples that harboured the ARPI extreme non-response programme.

The authors suggest exploring CDK2 inhibitors, currently in clinical trials in other cancer types, as a promising new direction in prostate cancers with the extreme ARPI non-responder programme.

Source: Michigan Medicine - University of Michigan